| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.96 [0.74, 1.24] | | < 1 | | 71% | 2 studies (2/-) | 62.2 % | low | not evaluable | high | crucial | - |
| progression or deaths (PFS) | 0.69 [0.61, 0.77] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | low | not evaluable | high | important | - |
safety endpoints 00 |
| AE (any grade) | 2.82 [1.34, 5.93] | | < 1 | | 51% | 2 studies (2/-) | 0.3 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 4.71 [0.91, 24.49] | | < 1 | | 95% | 2 studies (2/-) | 3.3 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 3.58 [2.19, 5.86] | | < 1 | | 62% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 4.60 [2.55, 8.28] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 3.15 [2.18, 4.57] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 2.55 [1.70, 3.82] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 17.86 [6.48, 49.27] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 6.77 [1.80, 25.50] | | < 1 | | 90% | 2 studies (2/-) | 0.2 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 5.04 [3.42, 7.41] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 9.16 [0.53, 158.85] | | < 1 | | 0% | 1 study (1/-) | 6.6 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 2.88 [2.05, 4.06] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 3.70 [2.43, 5.65] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 2.02 [0.18, 22.37] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 37.97 [2.28, 632.95] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 5.04 [0.27, 92.68] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 27.24 [9.27, 80.07] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 3.05 [0.61, 15.23] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 2.53 [0.55, 11.67] | | < 1 | | 0% | 1 study (1/-) | 11.7 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 28.89 [9.01, 92.57] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 10.19 [0.55, 187.21] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 4.05 [0.18, 90.01] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 2.30 [0.70, 7.52] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.03 [0.50, 8.18] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.50 [0.05, 5.57] | | < 1 | | 0% | 1 study (1/-) | 71.1 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 7.09 [0.40, 125.56] | | < 1 | | 0% | 1 study (1/-) | 9.3 % | NA | not evaluable | | non important | - |
| Neurologic TRAE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.87 [0.10, 7.48] | | < 1 | | 0% | 2 studies (2/-) | 55.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 6.69 [0.82, 54.44] | | < 1 | | 0% | 2 studies (2/-) | 3.9 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 8.13 [0.43, 154.37] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 4.02 [0.21, 76.42] | | < 1 | | 0% | 1 study (1/-) | 18.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.86 [0.29, 2.59] | | < 1 | | 0% | 1 study (1/-) | 60.5 % | NA | not evaluable | | non important | - |
| Acute kidney injury AE (grade 3-4) | 3.57 [0.74, 17.31] | | < 1 | | 0% | 1 study (1/-) | 5.7 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency AE (grade 3-4) | 2.02 [0.18, 22.37] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.93 [0.59, 1.47] | | < 1 | | 0% | 1 study (1/-) | 62.2 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 0.86 [0.29, 2.59] | | < 1 | | 0% | 1 study (1/-) | 60.5 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 2.09 [1.06, 4.12] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.69 [0.35, 1.40] | | < 1 | | 0% | 1 study (1/-) | 84.7 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders AE (grade 3-4) | 0.83 [0.54, 1.28] | | < 1 | | 0% | 1 study (1/-) | 79.7 % | NA | not evaluable | | non important | - |
| Cardiac disorders AE (grade 3-4) | 4.13 [1.16, 14.74] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 37.97 [2.28, 632.95] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.67 [0.11, 4.03] | | < 1 | | 0% | 1 study (1/-) | 66.8 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 4.05 [0.18, 90.01] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.27 [0.59, 2.75] | | < 1 | | 0% | 1 study (1/-) | 27.2 % | NA | not evaluable | | non important | - |
| Diabetes mellitus AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 10.81 [4.89, 23.91] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Dizziness AE (grade 3-4) | 1.01 [0.06, 16.17] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 2.67 [1.10, 6.46] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Endocrine disorders AE (grade 3-4) | 3.05 [0.61, 15.23] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 0.50 [0.02, 15.04] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Erythema AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Eye disorders AE (grade 3-4) | 0.60 [0.14, 2.53] | | < 1 | | 0% | 1 study (1/-) | 75.5 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 1.17 [0.73, 1.88] | | < 1 | | 0% | 1 study (1/-) | 26.1 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.01 [0.06, 16.17] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Gastritis AE (grade 3-4) | 8.13 [0.43, 154.37] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders AE (grade 3-4) | 3.31 [2.16, 5.08] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| General disorders and administration site conditions AE (grade 3-4) | 1.26 [0.89, 1.79] | | < 1 | | 0% | 1 study (1/-) | 9.7 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.01 [0.14, 7.19] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders (AE grade 3-4) | 7.16 [0.88, 58.50] | | < 1 | | 0% | 1 study (1/-) | 3.4 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 1.01 [0.06, 16.17] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Hypophysitis AE (grade 3-4) | 1.01 [0.06, 16.17] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 4.05 [0.18, 90.01] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 14.59 [1.91, 111.51] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 3.07 [0.82, 11.43] | | < 1 | | 0% | 1 study (1/-) | 4.8 % | NA | not evaluable | | non important | - |
| Infections and infestations AE (grade 3-4) | 2.13 [1.22, 3.71] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Injury, poisoning and procedure AE (grade 3-4) | 2.56 [0.80, 8.23] | | < 1 | | 0% | 1 study (1/-) | 5.8 % | NA | not evaluable | | non important | - |
| Investigations AE (grade 3-4) | 1.82 [1.17, 2.84] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.33 [0.03, 3.23] | | < 1 | | 0% | 1 study (1/-) | 82.7 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders AE (grade 3-4) | 1.88 [1.18, 2.99] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Mucosal inflammation AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Musculoskeletal and connective tissue disorders AE (grade 3-4) | 0.68 [0.44, 1.04] | | < 1 | | 0% | 1 study (1/-) | 96.2 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 3.04 [0.31, 29.34] | | < 1 | | 0% | 1 study (1/-) | 17.0 % | NA | not evaluable | | non important | - |
| Myopathy AE (grade 3-4) | 0.50 [0.02, 15.04] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.60 [0.61, 4.17] | | < 1 | | 0% | 1 study (1/-) | 16.8 % | NA | not evaluable | | non important | - |
| Nervous system disorders AE (grade 3-4) | 0.83 [0.49, 1.43] | | < 1 | | 0% | 1 study (1/-) | 74.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.17 [0.01, 3.34] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
| Paraesthesia AE (grade 3-4) | 1.01 [0.06, 16.17] | | < 1 | | 0% | 1 study (1/-) | 49.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.50 [0.02, 15.04] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.25 [0.01, 5.58] | | < 1 | | 0% | 1 study (1/-) | 80.6 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 4.13 [1.16, 14.74] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Proteinuria AE (grade 3-4) | 0.50 [0.02, 15.04] | | < 1 | | 0% | 1 study (1/-) | 65.2 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 5.09 [0.59, 43.77] | | < 1 | | 0% | 1 study (1/-) | 7.0 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 4.05 [0.18, 90.01] | | < 1 | | 0% | 1 study (1/-) | 19.2 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders AE (grade 3-4) | 1.11 [0.60, 2.04] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders AE (grade 3-4) | 1.68 [0.89, 3.19] | | < 1 | | 0% | 1 study (1/-) | 5.5 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 1.52 [0.25, 9.12] | | < 1 | | 0% | 1 study (1/-) | 32.6 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders AE (grade 3-4) | 12.26 [0.68, 220.32] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.37 [0.10, 1.42] | | < 1 | | 0% | 1 study (1/-) | 92.6 % | NA | not evaluable | | non important | - |
| Urticaria AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Uveitis AE (grade 3-4) | 2.02 [0.07, 60.32] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Vascular disorders AE (grade 3-4) | 1.45 [0.55, 3.85] | | < 1 | | 0% | 1 study (1/-) | 22.8 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.78 [0.29, 2.11] | | < 1 | | 0% | 1 study (1/-) | 68.7 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 5.09 [0.59, 43.77] | | < 1 | | 0% | 1 study (1/-) | 7.0 % | NA | not evaluable | | non important | - |
